An interventional study of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) and Percutaneous Transluminal Angioplasty (PTA) Device in Critical Limb Ischemia (CLI), sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Status unknown at 29 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-03-17.
Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Chronic Limb-Threatening Ischemia with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · China.
Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 with no phase, and was the 12th registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →7 of the 23 studies in Chronic Limb-Threatening Ischemia with a site in China are open now. Recruiting first, the newest first:
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
Allife Medical Science and Technology Co., Ltd. · Sites in China
Ages 18–80
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
Beijing Northland Biotech. Co., Ltd. · Sites in China
Ages 20–85
Beijing Tsinghua Chang Gung Hospital · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 2 · Phase 4 4
First in 2010; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 120 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 120 across the 15 interventional studies, 336 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Biotyx Medical (Shenzhen) Co., Ltd., one of the names counted as LifeTech Scientific Corporation. Under that name alone:
Biotyx Medical (Shenzhen) Co., Ltd. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
LifeTech Scientific Corporation has 2 studies filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Limb-Threatening Ischemia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06713850Liyuan Hospital of Tongji Medical College, Huazhong University of Science and TechnologyAngioplasty With Shockwave IVL Catheter System in Femoropopliteal Lesions | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Chronic Limb-Threatening Ischemia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, multi-center, randomized trial to assess the safety and effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating patients with infrapopliteal arterial stenosis or occlusive disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Device: Percutaneous Transluminal Angioplasty (PTA) Device
Subjects in this arm will be treated with IBS Titan™.
Subjects in this arm will be treated with PTA device.
Primary Patency Rate
Defined as freedom from total occlusion of target lesion and clinically driven target lesion revascularization (CD-TLR) of target lesion, and freedom from major amputation.
Time frame: 180 days
All-cause mortality
Time frame: 30 days, 180 days, 365 days
Incidence of Clinically-driven Target Vessel Revascularization (CD-TLR)
CD-TLR is defined as any TLR of target lesions associated with Rutherford category exacerbation and/or increasing in the size of preexisting wounds and/or the occurrence of new wounds.
Time frame: 30 days, 180 days, 365 days
Incidence of major amputation
Unplanned amputation of the lower limb above the ankle on the target lesion side
Time frame: 30 days, 180 days, 365 days
Rate of Device Success
Device success is defined on a per device basis, as the achievement of successful delivery, deployment of stent at the intended infrapopliteal target site(s) and successful withdrawal of the delivery catheter.
Time frame: Immediately after the procedure
Rate of Participants with Technical Success
Defined as restoration of blood flow in the target vessel and angiogram indicates the residual stenosis \<50%.
Time frame: Immediately after the procedure
Rate of Participants with Procedural Success
Defined as the combination of technical success, device success, and absence of procedural complications.
Time frame: Immediately after the procedure
Late Lumen Loss
Time frame: 180 days
Incidence of Target lesion restenosis
Defined as a reduction in the luminal diameter \>50% by angiography or CTA within the treated lesion plus the 5-mm segments proximal and distal to it or, as a peak systolic velocity ratio (PSVR) \>2.4 by DUS. Note 1: Doppler ultrasound will be performed at 30 days and 365 days, DSA angiography will be performed 180 days. Note 2: If the patient presented with CD-TLR in advance, i.e. the patient reached the endpoint in advance, the restenosis before reintervention was assessed.
Time frame: 30 days, 180 days, 365 days
Change in ankle-brachial index (ABI) compared to baseline (before treatment)
Time frame: 30 days, 180 days, 365 days
Change in Rutherford-Becker category compared to baseline (before treatment)
Categories and Clinical Description (higher scores mean a worse outcome): Category 0 = Asymptomatic, no hemodynamically significant occlusive disease, Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication, Category 4 = Ischemic rest pain, Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable.
Time frame: 30 days, 180 days, 365 days
Wound healing rate of ulcer patients
Time frame: 30 days, 180 days, 365 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Apr 2024, 28 months after the start.
Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →
Biotyx Medical (Shenzhen) Co., Ltd. →